Compass Therapeutics (CMPX) to Release Earnings on Thursday

Key Points

• Compass Therapeutics will release Q1 2026 results before the market opens on May 14; analysts expect ($0.10) EPS and about $0.82 million in revenue, and the company previously reported ($0.10) EPS for the quarter on May 5, matching consensus.
• Shares opened at $1.85, with a 52‑week range of $1.61–$6.88 and a market cap of $332.26 million; analysts are mixed but the consensus rating is a Moderate Buy with an average target price of $13.60.
• Institutional investors own roughly 68.43% of the stock, with recent large inflows and position increases from firms such as Vivo Capital (+57.9%), Vanguard (+45.6%) and Millennium Management (+280.4%).

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) is expected to release its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Compass Therapeutics to post earnings of ($0.10) per share and revenue of ($0.8180) million for the quarter. Parties may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 5, 2026 at 7:30 AM ET.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). On average, analysts expect Compass Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Compass Therapeutics Stock Performance

NASDAQ CMPX opened at $1.85 on Thursday. Compass Therapeutics has a fifty-two week low of $1.61 and a fifty-two week high of $6.88. The stock has a 50 day simple moving average of $5.02 and a two-hundred day simple moving average of $5.19. The stock has a market cap of $332.26 million, a P/E ratio of -4.50 and a beta of 0.79.

Analyst Ratings Changes

CMPX has been the subject of several research analyst reports. Jefferies Financial Group reiterated a "buy" rating and issued a $9.00 price objective on shares of Compass Therapeutics in a report on Thursday, March 5th. Wall Street Zen cut Compass Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, April 25th. Canaccord Genuity Group dropped their price objective on Compass Therapeutics from $13.00 to $7.00 and set a "buy" rating for the company in a report on Tuesday, April 28th. D. Boral Capital reiterated a "buy" rating and issued a $30.00 price objective on shares of Compass Therapeutics in a report on Monday, April 27th. Finally, William Blair reiterated an "outperform" rating on shares of Compass Therapeutics in a report on Thursday, March 5th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $13.60.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CMPX. Vivo Capital LLC increased its position in Compass Therapeutics by 57.9% during the 3rd quarter. Vivo Capital LLC now owns 9,545,466 shares of the company's stock valued at $33,409,000 after buying an additional 3,502,000 shares in the last quarter. Balyasny Asset Management L.P. bought a new stake in shares of Compass Therapeutics in the 3rd quarter worth $9,892,000. Braidwell LP bought a new stake in shares of Compass Therapeutics in the 4th quarter worth $14,965,000. Millennium Management LLC increased its holdings in shares of Compass Therapeutics by 280.4% in the 3rd quarter. Millennium Management LLC now owns 3,237,572 shares of the company's stock worth $11,332,000 after purchasing an additional 2,386,367 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Compass Therapeutics by 45.6% in the 3rd quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company's stock worth $24,720,000 after purchasing an additional 2,212,794 shares in the last quarter. Institutional investors own 68.43% of the company's stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.